anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Modular fluted tapered (MFT) femoral components are frequently utilized in aseptic revision total hip arthroplasties (THAs). However, long-term follow-up has been limited. The purpose of this study was to update our prior series at long-term follow-up, with specific emphasis on implant survivorship, radiographic results, and complications in a large cohort of aseptic revision THAs using MFT stems.
METHODS: We retrospectively identified 515 aseptic femoral revisions performed with 2 MFT stem designs in the total joint registry of a single tertiary care academic institution from 1999 to 2013. Serial radiographs were reviewed for subsidence of >5 mm. The mean follow-up (and standard deviation) was 10 ± 5 years (range, 2 to 21 years). A competing risk model accounting for death was utilized.
RESULTS: The 15-year cumulative incidence of any revision was 12%. There were 57 revisions, 27 of which involved revision of the fluted tapered component (FTC). Dislocation (n = 19), periprosthetic joint infection (n = 15), and aseptic loosening of the FTC (n = 11) were the most common reasons for revision. The 15-year cumulative incidence of any reoperation was 16%. The 15-year cumulative incidences were 6% for any FTC revision and 2% for FTC revision for aseptic loosening. Stem subsidence of >5 mm occurred in 2% of unrevised cases, and all but 1 stem was stable at the most recent follow-up.
CONCLUSIONS: This large series of MFT stems used in aseptic revision THAs had a 2% incidence of subsequent revision of the FTC for aseptic loosening at 15 years. Dislocation and infection were the most common reasons for any revision.
LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
The invention comprises compounds of formula <FORM:1000405/C2/1> wherein X is sulphur or oxygen, R is a hydrogen atom or a methyl, ethyl or propyl group, and Z is an alkylaminoalkyl group wherein Z is of formula -CHR1-(CH2)n-NAA or -(CH2)n-CR1R1-NAA wherein each R1 is hydrogen or a methyl, ethyl or propyl group, n is 0, 1, 2 or 3, and A is an alkyl group or -NAA forms a heterocyclic ring, and wherein one or more of the 4, 5, 6 and 7 positions in the benz-ring and/or the vacant positions in the phenyl group may be substituted by chlorine, bromine or iodine atoms or methyl, methoxy, nitro or amino groups, acid addition and quaternary ammonium salts thereof.  These compounds are prepared by reaction of the appropriate mercaptobenzazole with the appropriate substituted benzyl chloride.  The compounds of the invention have antifungal and antibacterial activity.  3 - Chloro - 4 - diethylaminoethoxy - benzyl chloride hydrochloride is prepared by reacting 3 - chloro - 4 - hydroxy - benzaldehyde with sodium in ethanol and with b -diethylaminoethyl chloride to give 3-chloro-4-diethylaminoethoxy-benzaldehyde, converting this either by hydrogenation or by treatment with paraformaldehyde and alkali to 3-chloro-4-diethylaminoethoxy-benzyl alcohol, and treating this with thionyl chloride.  4 - Diethylaminoethoxy - a  - methyl - benzyl chloride hydrochloride is prepared by reacting 4 - diethylaminoethoxy - benzaldehyde with methyl magnesium iodide to give 4-diethylaminoethoxy - a  - methyl - benzyl alcohol, and treating this with thionyl chloride.  Specification 825,016 is referred to.
Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
The present invention discloses a kind of Chinese proprietary medicine for treating cardiocerebrovascular disease, specially for treating cerebral infarct ion caused by cerebral thrombosis cerebral atrophy and the sequel of hemiplegia, slurred speech and aphasia, etc. diseases. The medicinal components consist of saffron, spatholobus stem, rhizome of davallia, purple gromwell root, Ligusticum wallichii, unpeeled root of herbaceous peony, myrrh, psudo ginseng etc. 44 traditional Chinese medicinal herbs by specific proportion. The medicament is prepared up by leaching the above mentioned medicines in spirit. The peculiarities are quick effective, no recur-rence, and cheap price.
FIELD: medicine, gastroenterology. SUBSTANCE: invention proposes carrying out the complex therapy using preparations that promote the improvement of intestine motor system and digestion and vitamin therapy. At onset of the complex therapy anti-HLA serum against antigen class-I of patient diluted with human donor albumin is administrated by rectal route. The total volume of administrated mixture is 100 ml, 3 times at break for 2 days. Then rectal spraying large intestine mucosa is carried out with preparations containing living lyophilized bifidobacteria (5 doses diluted in 80 ml of albumin, 5 times at break for 2 days). EFFECT: enhanced effectiveness of treatment. 1 ex
A composition of matter comprising a Tc-99m labeled antibody and diagnostic kits for forming same are provided. The labeled antibody is anti-human chorionic gonadotropin (anti-hCG) or anit-human chorionic gonadotropin-beta subunit (anti-hCG-β) or a mixture thereof. In diagnostic use, the labeled antibody is administered in physiologically and pharmaceutically acceptable form and its biodistribution is monitored. The labeled antibody will accumulate at cancer sites e.g. tumors that produce human chorionic gonadotropin, human chorionic gonadotropin-like material. comPounds similar or identical to the β-chain of chorionic gonadotropin and mixtures thereof, which bind specifically to anti-hCG and/or anti-hCG-β.
A microsphere making device includes a substrate, a first micro channel, a second micro channel, a first mix micro channel and a third micro channel, which are located inside the substrate. The first micro channel includes a fore-guiding micro channel and a space inside a thin long tube embedded in the substrate, which are connected together. An end of the thin long tube has a thin tube outlet and the first micro channel is set at a first inlet of the for-guiding micro channel. Two second micro channels respectively have a second inlet, and the second micro channels respectively connect the thin tube outlet of the first micro channel at the left and right sides of the micro channel so that a configuration of three-way confluence is formed. The first mix micro channel connects the confluence where the thin tube outlet and the two second micro channels meet. The first mix micro channel has an outlet. The third micro channel connects one side of the first mix micro channel and has a third inlet.
Participants receive the traditional core course along with a 20-minute video feedback session. Initially, a therapist records students' assessment techniques in action, capturing the dynamic process on video. The recorded video is then played on a screen for both the course teacher and students to watch together. Participants can annotate specific actions during the viewing, and the course teacher facilitates a reflective discussion where participants observe and identify any issues or correct actions as expected. The teacher provides feedback on areas of improvement in the action process for further practice. The self-viewing of the recorded video serves as a valuable tool for enhancing the skill performance of physical therapy interns.
In this retrospective longitudinal cohort study, we investigated the temporal changes in the peripapillary retinal nerve fiber layer (pRNFL) and inner retinal thickness in patients with acute central serous chorioretinopathy (CSC) using spectral-domain optical coherence tomography (SD-OCT). We followed up with these patients for 6 months, and during this period, the thickness of the pRNFL and the ganglion cell complex (GCC) in CSC patients were compared with the eyes of normal healthy individuals. The study also examined the correlation between the pRNFL thickness, GCC thickness, and visual acuity. The research sample consisted of 67 patients (43 male and 24 female) with an average age of 49.72 ± 9.87 years. The initial findings showed no significant differences in the pRNFL and GCC thickness between the study and fellow eye, study and normal healthy eyes, and fellow and normal healthy eyes. There was no significant difference in the pRNFL and GCC thickness when comparing the study eye with the fellow eye for 6 months. In the study eye, no significant difference was observed when comparing the initial GCC and pRNFL thickness with those at 1, 3, and 6 months. Visual acuity improved significantly from 0.18 ± 0.23 logMAR to 0.04 ± 0.06 logMAR (p < 0.001). The GCC and pRNFL thickness did not significantly affect visual acuity. In conclusion, acute CSC patients did not show significant changes in the pRNFL and inner retinal thickness, suggesting that the GCC and pRNFL do not substantially influence the short-term visual prognosis in these patients.
Numerous myofibroblasts are arisen from endothelial cells (ECs) through endothelial to mesenchymal transition (EndMT) triggered by TGF-β. However, the mechanism of ECs transforms to a different subtype, or whether there exists an intermediate state of ECs remains unclear. In present study, we demonstrate Midkine (MDK) mainly expressed by CD31 + ACTA2+ECs going through partial EndMT contribute greatly to myofibroblasts by spatial and single-cell transcriptomics. MDK is induced in TGF-β treated ECs, which upregulates C/EBPβ and increases EndMT genes, and these effects could be reversed by siMDK. Mechanistically, MDK promotes the binding ability of C/EBPβ with ACTA2 promoter by stabilizing the C/EBPβ protein. In vivo, knockout of Mdk or conditional knockout of Mdk in ECs reduces EndMT markers and significantly reverses fibrogenesis. In conclusion, our study provides a mechanistic link between the induction of EndMT by TGF-β and MDK, which suggests that blocking MDK provides potential therapeutic strategies for renal fibrosis.
<P>PROBLEM TO BE SOLVED: To provide a new process for preparing himbacine analogs useful as thrombin receptor antagonists.  <P>SOLUTION: There is provided the new process for preparing compound 11 from compound 1 (each described in the specification). The process provides an improved yield and the elimination of the need for chiral intermediates. The process is partially based on the use of base-promoted type dynamic epimerization of a chiral nitro center. In another embodiment, there are provided the compounds prepared by the process.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Long-term studies in animals to determine the carcinogenic potential of telavancin have not been performed. 

Neither mutagenic nor clastogenic potential of telavancin was found in a battery of tests including: assays for mutagenicity (Ames bacterial reversion), an in vitro chromosome aberration assay in human lymphocytes, and an in vivo mouse micronucleus assay. 

Telavancin did not affect the fertility or reproductive performance of adult male rats (up to 100 mg/kg/day for at least 4 weeks prior to mating) or female rats ( up to 150 mg/kg/day for at least 2 weeks prior to mating). 

Male rats given 50 or 100 mg/kg/day telavancin for 6 weeks, at exposure levels similar to those measured in clinical studies, displayed altered sperm parameters that were reversible following an 8-week recovery period. A longer dosing period showed that telavancin caused histopathological changes in the seminiferous tubules and epididymides of the rat testis after 13 weeks of administration at 50 or 100 mg/kg/day. These changes were reversible at the end of a 4 week recovery period.
Two cohorts of elderly healthy volunteers and elderly patients undergoing abdominal surgery will be included in this study. The cognitive function of the patients was tested one day before and seven days after operation. Healthy volunteers had two cognitive function tests at the same interval. The normality test is used to evaluate whether the test results accord with the normal distribution. The internal consistency of the test was evaluated by calculating the Cronbach coefficient, the content validity was evaluated by experts and the content validity index was calculated, and the construct validity of the test was evaluated by exploratory factor analysis and confirmatory factor analysis. The validity of the test was evaluated by calculating the effect scale.
There are several studies investigating the beneficial effects of exercise on physical function among elderly. However the trials that reporting beneficial effects of an exercise programme on psychosocial functions such as depression and falls efficacy are scarcend. And also these trials are designed to compare fully supervised experimental group with a control group receiving usual care. In only one, out of these studies, supervision was minimal and delivered via home visit. However no psychosocial function related outcome measure was evaluated. In the present study the investigators have intended to assess the effects of minimally supervised home exercise programme on physical and psychosocial fall related variables by comparing with unsupervised home exercise programme in community-dwelling older adults.
Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines. Also disclosed herein are methods of eliciting an immune response in a subject against one or more coronavirus antigens and methods of preventing, reducing the incidence of, attenuating, or treating coronavirus infection in a subject in need thereof.
The lymphocyte activation gene (LAG-3) is a member of the immunoglobulin superfamily that is selectively transcribed in human activated T and NK cells. Surface LAG-3 expression correlated with IFN-.gamma. but not IL-4, production in antigen-stimulated T-cells and it was up-regulated by IL-12 and is preferentially associated with CD4+ T-cells producing Th1-type cytokines. The presence of LAG-3 on the surface of Th1 lymphocytes is used as a marker to detect and identify Th1 lymphocytes and differentiate them from Th2 lymphocytes. Monoclonal antibodies to LAG-3 are used in methods of detecting and isolating Th1 cells as well as methods of diagnosing Th1-mediated disease. The present invention also relates to methods of treating infectious diseases, cancer, and disorders associated with Th1/Th2 imbalance.
Fatty acid synthase (FASN) is a critical enzyme essential for the production of fats in the body. The abnormal expression of FASN is associated with different types of malignancies, including ovarian cancer. FASN plays a crucial role in cell growth and survival as a metabolic oncogene, although the specific processes that cause its dysregulation are still unknown. FASN interacts with signaling pathways linked to the progression of cancer. Pharmacologically inhibiting or inactivating the FASN gene has shown potential in causing the death of cancer cells, offering a possible treatment approach. This review examines the function of FASN in ovarian cancer, namely its level of expression, influence on the advancement of the disease, and its potential as a target for therapeutic interventions.
The molecular classification of endometrial carcinoma and the resulting studies have contributed to the recent ESGO/ESTRO/ESP guidelines for the management of patients diagnosed with endometrial carcinoma . To date, however, this molecular classification has mostly been performed in the context of clinical trials or in retrospective research contexts and is only now beginning to be implemented in the clinical workflow.

Endometrial carcinomas with pathogenic mutations of the POLE gene have demonstrated an excellent clinical outcome in terms of RFS and OS in the early stages of the disease (stage I and II), especially in high-grade carcinomas. Furthermore, 3-5% of endometrial carcinomas present multiple molecular alterations. In particular, the literature suggests that POLE-mutated cases that are at the same time TP53-mutated or MMR-deficient have a clinical behavior like cases with only POLE alteration. Overall, POLE-mutated tumors would therefore not require adjuvant therapy unlike carcinomas belonging to other molecular groups (TP53-mutated, MMRd and NSMP) or which are attributable to the intermediate-high risk group according to the guidelines . The PORTEC-4A study is also underway for this group.In a cohort of 23 POLE-mutated endometrial carcinomas Stasenko and colleagues documented recurrence in 17% of cases, suggesting caution in omitting adjuvant therapy. A very recent work on 310 endometrial carcinomas studied from a morpho-molecular perspective, including 15 POLE-mutated tumors, however has follow-up data that are too short to be conclusive (11.6 months on average). Advanced stage POLE-mutated carcinomas (III-IVA) are also rare and poorly described in the literature. It therefore seems appropriate to prospectively collect real-world clinical-pathological data on a large scale from patients with POLE-mutated tumors with the aim of investigating the histo-molecular characteristics of patients who undergo relapse and being able to compare them with those of non-relapsed patients. relapse. The relative rarity of POLE-mutated tumors in general and in particular of those that relapse suggests the need to involve multiple centers in order to obtain a significant number.
Initiate therapy with Allopurinol Sodium for Injection 24 to 48 hours before the start of chemotherapy known to cause tumor cell lysis. Additionally, administer fluids sufficient to yield a daily urinary output of at least two liters in adults with a neutral or, preferably, slightly alkaline urine. 

The recommended daily dose of Allopurinol Sodium for Injection is shown in Table 1. Administer the daily dose as single infusion or in equally divided infusions at 6-, 8-, or 12-hour intervals at a rate appropriate for the volume of infusate.

The dosage of Allopurinol Sodium for Injection to lower serum uric acid to normal or near-normal varies with the severity of the disease. Monitor serum uric acid levels at least daily and administer Allopurinol Sodium for Injection at a dose and frequency to maintain the serum uric acid within the normal range. Discontinue Allopurinol Sodium for Injection when the patient is able to take oral therapy or when the risk of tumor lysis has abated.
Participants assigned to the Delayed Intervention Group will receive a "Welcome Box" which on the outside is identical (and also is comparably weighted with bottled water) to that given to the Immediate Intervention group. This box would include: 1) Letters describing the project logistics and the important roles of each dyad member; and 2) monthly online study newsletters on topics unrelated to diet and exercise, but still of interest to cancer survivors and dyad members such as coping with stress, reducing exposure to radiation, sun safety, etc. to enhance retention and will be offered the opportunity to receive the online intervention after completing final 6-month assessments.
FIELD: microbiology, vaccines. SUBSTANCE: invention relates to preparing live culture vaccines against carnivores plague. For vaccine preparing a new attenuated strain "VNIIVVim-88" (registration number is "VNIIVVim Dep" in VGNKI collection) is used. Highly sensitive subline CV-1 of an African green monkey transplanted kidney cells is used as a cellular system for virus culturing and for drying medium - a medium of the corresponding composition based on protein products hydrolysis. Monolayer cell culture of subline CV-1 is maintained by serial passage and virus culturing in transplanted cell culture is carried out under roller conditions. Collection of virus-containing material is carried out at virus titer up to 3.5-4.5 lg TCD 50/cu. cm. Material is mixed with protective medium at volume ratio 3:2. Value pH is corrected at the range 6.4-6.8 and material is lyophilized. Method exhibits high productivity, simplified procedure, availability and easily realized in industrial scale. Vaccine produced by new method shows the enhanced effectiveness by immunogenicity, safety, stability at storage, harmless and low cost. EFFECT: improved method of preparing, high quality and properties of vaccine. 1 tbl, 3 ex
Patients receive lymphodepletion chemotherapy with cyclophosphamide IV daily on Days -7 to -6 and fludarabine IV daily on Days -5 to -1. Patients receive HER2 CAR T cells IV on Day 0 followed by surgical tumor resection 4-6 weeks following HER2 CAR T cell infusion. Treatment repeats every 8 to 15 weeks for 2 additional cycles in the absence of disease progression or unacceptable toxicity.
Vitamin concentrates are obtained from oleaginous vitamin-containing materials by saponifying, e.g. with potassium hydroxide, the oleaginous material to form a soap mass, extracting the soap mass with a hydrocarbon or halogenated hydrocarbon, e.g. ethylene di-chloride, or a mixture of such solvents while maintaining the temperature of the solvent and the soap between about 40 DEG  C. and just below the boiling point of the solvent, and separating the warm solvent from the warm soap, the process being characterized in that the water content of the soap during the extraction is maintained at such an amount that the soap is slightly soluble in the solvent, i.e. the soap is less than 1 per cent soluble in the solvent.  As starting materials there may be used substances of marine origin, e.g. fish liver oils.  Detailed examples are given.  Specification 550,845 is referred to.
Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
A standard high volume bowel-prep, used for a long time in Sweden. The dose is 2000 ml x 2. The first dose is given the evening before the colonoscopy and the second dose is given 4-5 hours before the colonoscopy.
Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
The Training of the control-group is performed by regular recommendations/ Standard of care. Standard of care in this context means to hand out the brochure " Besser Leben mit COPD " including an emergency plan, providing exercise training examples, to hand out addresses of out-patient physiotherapists and to hand out a detailed medical report including medical recommendations.Additionally, the Polar A370 watch will collect the daily symptoms and training log during each session for the Database.